Keryx (KERX) Says Zerenex Phase 3 Met Primary, Secondary Endpoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Keryx Biopharmaceuticals (KERX) Continues Monumental Run-Up; Analysts See Another 40% Upside
January 29, 2013 10:50 AM ESTKeryx Biopharmaceuticals, Inc. (NASDAQ: KERX) continues to surge on the back of positive Phase III trial evaluating Zerenex. After yesterday's 77% surge, shares are up another 37% early Tuesday.
A number of analysts are out positive on the stock and have new price target showing... More
Oppenheimer Lifs PT on Keryx Biopharmaceuticals (KERX) to $11
January 29, 2013 8:42 AM ESTOppenheimer boosted its price target on Outperform-rated Keryx Biopharmaceuticals (NASDAQ: KERX) from $3 to $11 following positive Phase III trial evaluating Zerenex for the treatment of hyperphosphatemia in dialysis patients.
Analyst Boris Peaker, PhD comments, "Primary and key secondary endpoints were met and the... More
Stifel Nicolaus Boosts Keryx Biopharmaceuticals (KERX) PT to $13
January 29, 2013 8:37 AM ESTStifel Nicolaus raised its price target on Buy-rated Keryx Biopharmaceuticals (NASDAQ: KERX) from $4 to $13 following positive Phase 3 results for Zerenex.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more... More
Burrill Lifts PT on Keryx Biopharmaceuticals (KERX) to $11
January 29, 2013 8:04 AM ESTBurrill raised its price target on Keryx Biopharmaceuticals (NASDAQ: KERX) from $6 to $11 following positive Phase 3 results for Zerenex. The firm maintained a Market Outperform rating.
"Based on the clinically differentiated profile demonstrated in the Phase 3 clinical study, we believe Keryx should... More
Keryx Biopharmaceuticals (KERX) Gets Another 'Going to $15' Call
January 28, 2013 12:48 PM ESTAnother analyst is on the Keryx Biopharmaceuticals (NASDAQ: KERX) 'going to $15' bandwagon following positive Phase 3 data.
In addition to Roth Capital... More
Roth Capital Doubles PT on Keryx (KERX); Sees Another 200% Upside
January 28, 2013 11:27 AM ESTRoth Capital's Joseph Pantginis boosted his price target on Keryx Biopharmaceuticals (NASDAQ: KERX) from $7 to $15 following his morning's... More
Keryx Biopharmaceuticals (KERX) Ramps 38% Upon Trade Resumption
January 28, 2013 7:41 AM ESTKeryx Biopharmaceuticals, Inc. (NASDAQ: KERX) resumed trading and is higher by 38 percent following positive Phase 3 trial data.... More
